投资者青睐更安全、市场成熟度高的生物科技项目，早期融资缺口进一步扩大。
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
生命科学资讯
生物技术与制药领域的最新动态
Mirum加倍押注多元化罕见病战略。
Mirum doubles down on diversified rare disease strategy
尽管AI已进入高风险患者护理领域，监管却滞后不前。
AI regulation lags despite entering higher-risk patient care
2026年制药业展望：前路是否更加顺畅？
Pharma’s outlook in 2026: Smoother sailing ahead?
大型制药企业如何应对3000亿美元专利悬崖
How Big Pharma is navigating a $300 billion patent cliff
FDA政治化程度空前加深，长期影响堪忧
Politicization runs deeper than ever at FDA, risking long-term impacts
礼来与BioAge竞逐NLRP3抑制剂，探索“一药多靶点”潜力。
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
诺瓦瓦克斯是否已在疫苗领域破解生存密码？
Has Novavax cracked the code for survival in the vaccine arena?
心力衰竭潜在基因疗法，数十年研究终现曙光。
A potential gene therapy for heart failure is an approach decades in the making
生物制药行业去年裁员潮涌，但2026年或迎转机。
Biopharma layoffs surged last year, but 2026 is a chance to turn the page
大型制药公司收购中国生物科技企业以充实GLP-1药物管线
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
美国药品定价政策成投资者“红灯”，中国市场成新机遇
US drug pricing policies are ‘red lights’ for investors, and China beckons
癌症研发蓬勃发展，2026年值得关注的领域。
Cancer R&D is thriving. Here are the areas to watch in 2026.
礼来与武田制药遭法律策略锁定，通常此类手段仅用于打击黑帮。
Lilly, Takeda targeted by legal strategy usually reserved for the mob
德克萨斯、北卡罗来纳、俄亥俄、宾夕法尼亚——制药制造业投资激增之地
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
特朗普公布医疗可负担性计划
Trump unveils healthcare affordability plan
制药高管关注的临床候选药物
The clinical candidates pharma execs are tracking
美国生物制药并购迎来关键时刻，药企能否克服持续焦虑达成交易？
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
礼来与诺和诺德测试直供雇主模式，或可绕过药品福利管理公司降低成本。
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
马萨诸塞州生物制药行业呈现三大积极趋势
3 positive trends for Massachusetts’ biopharma sector